Blautia hydrogenotrophica Strain Modulation for Lung Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for lung injury and lung diseases such as asthma, ARDS, and COPD are inadequate, with a need for new treatments that effectively address inflammation and microbial imbalance in the gut-lung axis.
Innovation Solution
The use of compositions comprising bacterial strains of the species Blautia hydrogenotrophica, specifically strain DSM 14294, which are administered orally to reduce lung inflammation and treat lung injury or disease by colonizing the intestine and modulating the microbial balance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for lung injury and lung diseases, then treatment is provided, but the therapies are inadequate and do not effectively address inflammation and microbial imbalance
Solution Approach 1:
The patent introduces Blautia hydrogenotrophica bacteria as an intermediary organism that mediates the gut-lung axis communication. These bacteria colonize the gut and produce metabolites that systematically reduce lung inflammation, effectively bridging the gap between gut microbial balance and lung health. This intermediary approach overcomes the limitations of conventional therapies by addressing both inflammation and microbial imbalance through a biological mediator.
2Reliability
If new therapies targeting the gut-lung axis are developed, then treatment effectiveness for lung diseases improves, but the relationship between bacterial strains and diseases is poorly characterised
Solution Approach 1:
The patent performs preliminary characterization of Blautia hydrogenotrophica strains before clinical application. Extensive in vitro and in vivo studies were conducted to establish the strain's identity, safety profile, and therapeutic mechanisms. This preliminary research phase captured critical information about the bacterial strain's properties and its specific effects on lung inflammation, creating a knowledge base that informs subsequent therapeutic use and prevents information loss.
3Object-affected harmful factors
If bacterial strains are used to treat lung diseases, then inflammation reduction is achieved, but the precise effects on the gut and other tissues at a systemic level are poorly characterised
Solution Approach 1:
The patent employs comprehensive feedback mechanisms to monitor and characterize the systemic effects of Blautia hydrogenotrophica administration. Multiple assessment methods including gut microbiota sequencing, metabolic profiling, and systemic inflammation markers were used to capture feedback information about the bacteria's effects beyond the lungs. This feedback loop enabled detailed characterization of systemic effects while confirming the primary anti-inflammatory benefit in lung tissue.
Data Source
AI summary
The invention provides compositions comprising bacterial strains for treating and preventing lung injury or lung disease.